ATE401394T1 - Verbesserte dnase flüssige lösungen - Google Patents

Verbesserte dnase flüssige lösungen

Info

Publication number
ATE401394T1
ATE401394T1 AT95911123T AT95911123T ATE401394T1 AT E401394 T1 ATE401394 T1 AT E401394T1 AT 95911123 T AT95911123 T AT 95911123T AT 95911123 T AT95911123 T AT 95911123T AT E401394 T1 ATE401394 T1 AT E401394T1
Authority
AT
Austria
Prior art keywords
dnase
solutions
calcium ion
liquid solutions
thermal aggregation
Prior art date
Application number
AT95911123T
Other languages
English (en)
Inventor
Hak-Kim Chan
Igor Gonda
Steven Shire
Suzanne Weck
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE401394T1 publication Critical patent/ATE401394T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/534—Mentha (mint)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9068—Zingiber, e.g. garden ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21001—Deoxyribonuclease I (3.1.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Jellies, Jams, And Syrups (AREA)
AT95911123T 1994-03-04 1995-02-28 Verbesserte dnase flüssige lösungen ATE401394T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20650494A 1994-03-04 1994-03-04
US37752795A 1995-01-20 1995-01-20

Publications (1)

Publication Number Publication Date
ATE401394T1 true ATE401394T1 (de) 2008-08-15

Family

ID=26901408

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95911123T ATE401394T1 (de) 1994-03-04 1995-02-28 Verbesserte dnase flüssige lösungen

Country Status (7)

Country Link
US (2) US6383788B1 (de)
EP (1) EP0748377B1 (de)
JP (1) JP3009224B2 (de)
AT (1) ATE401394T1 (de)
CA (1) CA2184581C (de)
DE (1) DE69535787D1 (de)
WO (1) WO1995023854A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3009224B2 (ja) * 1994-03-04 2000-02-14 ジェネンテック インコーポレイテッド 改良されたｄｎアーゼ液体溶液
AU733602B2 (en) * 1996-09-04 2001-05-17 Nexell Therapeutics Inc. Compositions containing nucleases and chelators to enhance the recovery of cells during cell separating procedures
SI1324776T2 (en) 2000-10-12 2018-06-29 Genentech, Inc. Concentrated protein formulations with reduced viscosity
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
SG174258A1 (en) 2009-03-06 2011-10-28 Genentech Inc Antibody formulation
JP5921545B2 (ja) 2010-08-11 2016-05-24 アイアンウッド ファーマシューティカルズ インコーポレイテッド リナクロチドの安定な製剤
WO2016067944A1 (ja) 2014-10-31 2016-05-06 Ｊｃｒファーマ株式会社 組換えヒトＤＮａｓｅＩの製造方法
RU2017125957A (ru) * 2015-01-04 2019-02-04 Проталикс Лтд. Модифицированная днказа и ее применения
WO2017049205A2 (en) * 2015-09-18 2017-03-23 Amunix Operating Inc. Growth hormone formulation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3042587A (en) * 1960-11-29 1962-07-03 Merck & Co Inc Stabilized desoxyribonuclease preparation
CA1059937A (en) 1975-03-25 1979-08-07 Boen T. Khouw Isolation and purification of deoxyribonuclease
US4233405A (en) * 1979-10-10 1980-11-11 Rohm And Haas Company Process for spray drying enzymes
ATE176924T1 (de) * 1988-12-23 1999-03-15 Genentech Inc Verfahren zur herstellung von menschlicher dnase
US5279823A (en) * 1992-06-08 1994-01-18 Genentech, Inc. Purified forms of DNASE
JP3009224B2 (ja) * 1994-03-04 2000-02-14 ジェネンテック インコーポレイテッド 改良されたｄｎアーゼ液体溶液
US5580856A (en) * 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof

Also Published As

Publication number Publication date
US20030054532A1 (en) 2003-03-20
DE69535787D1 (de) 2008-08-28
EP0748377B1 (de) 2008-07-16
US7018825B2 (en) 2006-03-28
JP3009224B2 (ja) 2000-02-14
WO1995023854A1 (en) 1995-09-08
CA2184581C (en) 2005-02-22
CA2184581A1 (en) 1995-09-08
JPH09503394A (ja) 1997-04-08
US6383788B1 (en) 2002-05-07
EP0748377A1 (de) 1996-12-18

Similar Documents

Publication Publication Date Title
SE9503143D0 (sv) New preparation
AU2506388A (en) Azelastine-containing medicaments for application in the nose and/or at the eye
TR199801180T2 (xx) Aneljestik etkiye sahip yeni bile�ikler.
HUP0102033A2 (hu) PEG IFN-alfa és ribavirin felhasználása krónikus hepatitis C kezelésére
CA2059403A1 (en) Use of Carrageenans in Topical Ophthalmic Compositions
IT1246188B (it) Procedimento per la preparazione di composizioni farmaceutiche aventi aumentata velocita' di dissoluzione della sostanza attiva e composizioni ottenute.
ATE234108T1 (de) Therapeutikum zur unterdrückung von schnarchgeräuschen
BR9814924A (pt) Microgrânulos de omeprazol, processo de preparação dos mesmos, e, preparações farmacêuticas
DE69535787D1 (de) Verbesserte dnase flüssige lösungen
EP0177342A3 (de) Orale Formulierungen therapeutischer Proteine
IE891118L (en) Topical preparation for treating otopathy
ATE293451T1 (de) Behandlung der osteoarthritis durch verabreichung von poly-n-acetyl-d-glucosamin
PT1032379E (pt) Composicao com acido azelaico
BR9803233A (pt) Preparação de combinação farmacêutica de um inibidor do trocador de sódio/hidrogênio e um medicamento para o tratamento de doenças cardiovasculares.
BG60101B2 (bg) Метод за получаване на 4-флуор-2-(((4-метокси-2- пиридинил)метил)тионил)-1н-бензимидазол
TR199801184T2 (xx) Analjezik tesirli yeni bile�ikler.
RU98111152A (ru) Применение активного вещества флупиртина или его фармакологически приемлемых солей в качестве лекарственного средства для профилактики и лечения заболеваний, ассоциированных с повреждением клеточной системы гемопоэза
NO884123D0 (no) Stabilisering av terapeutisk virksomme proteiner i farmasoeytiske preparater.
HUP9901659A2 (hu) Flupirtin alkalmazása a hematopoetikus sejtrendszer károsodásával kapcsolatos megbetegedések megelőzésére és gyógyítására alkalmas gyógyszerkészítmény előállítására
ATE233085T1 (de) Arzneimittel zur topischen anwendung
IE840977L (en) Pharmaceutical preparations
KR960003718A (ko) 말초신경병 및 중추신경변성병의 치료에 유용한 의약의 제조를 위한 이펜프로딜 및 그 부분입체이성질체의 이용
RU94045140A (ru) Фармацевтическая композиция для профилактики или лечения вирусных заболеваний, способ ее получения и применение антагониста брадикинина или его физиологически переносимой соли в качестве средства для профилактики или лечения вирусных заболеваний
DE60217302D1 (de) Erhaltung von körpereigenen proteinen
CA2130988A1 (en) Pharmaceutical Composition for Treatment of Sudden Deafness

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties